ALLUVI: A DEEP DIVE INTO THE DRUG'S PROMISE

Alluvi, formerly LY3414901, represents a noteworthy advancement in obesity management. This dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receiver agonist demonstrates remarkable effectiveness in early clinical data, with impressive reduction